CatalYm Initiates Phase 2/3 Trial of Visugromab in Cancer Cachexia with First Patient Dosed CatalYm has announced an important milestone in its clinical development pipeline with the dosing of the first patient in its pivotal Phase 2/3 VINCIT trial (Visugromab…
Kallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting Kallyope, a late-stage biopharmaceutical company focused on developing innovative treatments for neurological and metabolic disorders, has announced promising results from a…
As Federal Fast-Tracking of Psychedelic Treatments Gains Momentum, Segal Trials Is Poised to Advance the Next Stage of Clinical Development The recent federal directive encouraging the U.S. Food and Drug Administration to accelerate the review of psychedelic-based therapies signals a…
AV Laboratories Transforms IVF Science into Breakthrough Skin Longevity Innovations AV Laboratories is positioning itself at the forefront of a new era in skincare by bringing together decades of advanced biotechnology research and translating it into clinically inspired formulations designed…
Agenus to Showcase Initial Phase 2 Botensilimab Results in Advanced Cutaneous Melanoma at ASCO 2026 Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company focused on developing next-generation cancer immunotherapies, announced today that four scientific abstracts featuring its lead checkpoint inhibitor…
Speak Foundation Introduces Patient-Led National LGMD Centers of Excellence to Drive Clinical Trials and Innovative Treatments Speak Foundation has announced the launch of a major new initiative aimed at transforming care delivery and accelerating therapeutic development for patients living with…
RareCyte Broadens Clinical-Scale Spatial Proteomics Offering with New Orion Systems and Leadership Addition RareCyte has announced a major expansion of its spatial proteomics capabilities, marking a strategic step forward in its mission to advance biomarker-driven research and precision medicine. The…
Synthetic Design Lab reveals first logic-gated ADC at AACR 2026 with ≥10x enhanced targeted cancer cell killing Synthetic Design Lab, an emerging innovator in the field of antibody-drug conjugates (ADCs) and advanced protein engineering, has unveiled compelling preclinical findings that…
Zai Lab reports strong, rapid brain metastasis responses with Zocilurtatug Pelitecan in SCLC and other neuroendocrine cancers Zai Lab Limited has unveiled compelling new clinical and preclinical data highlighting the potential of its oncology pipeline, led by zocilurtatug pelitecan (zoci,…
Onchilles Pharma Presents at AACR 2026 New Preclinical Data from the Systemically Delivered NEU-002 Program, Supporting Advancement Toward Development Candidate Selection Onchilles Pharma, a privately held biotechnology company focused on advancing next-generation cancer therapeutics targeting the ELANE pathway, has unveiled…
Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026 At the ESCMID Global 2026, the Microbiology & Infection Diagnostics division of Bruker Corporation unveiled a major advancement in molecular diagnostics with the European launch of the MyGenius PRO.…
Nucleai and Sirona Dx Partner to Deliver an Integrated Spatial Proteomics Solution for Pharma Drug Development Nucleai, a leader in AI-powered spatial biology analytics, and Sirona Dx, a Technical CRO, specialized in spatial biology and single-cell services, today announced a…